Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
HIGHLIGHTSFibroproliferation is present early in LPS‐induced acute lung injury.Pirfenidone ameliorates LPS‐induced pulmonary inflammation and fibrosis.The efficacy of pirfenidone is associated with inhibition of NLRP3 inflammasome activation. ABSTRACT Acute respiratory distress syndrome(ARDS)is a severe clinical disorder characterized by its acute onset, diffuse alveolar damage, intractable hypoxemia, and non‐cardiogenic pulmonary edema. Acute lung injury(ALI) can trigger persistent lung inflammation and fibrosis through activation of the NLRP3 inflammasome and subsequent secretion of mature IL‐1&bgr;, suggesting that the NLRP3 inflammasome is a potential therapeutic target for ALI, for which new therapeutic approaches are needed. Our present study aims to assess whether pirfenidone,with anti‐fibrotic and anti‐inflammatory properties, can improve LPS‐induced inflammation and fibrosis by inhibiting NLRP3 inflammasome activation. Male C57BL/6J mice were intratracheally injected with LPS to induce ALI. Mice were administered pirfenidone by oral gavage throughout the entire experimental course. The mouse macrophage cell line (J774A.1) was incubated with LPS and ATP, with or without PFD pre‐treatment. We demonstrated that PFD remarkably ameliorated LPS‐induced pulmonary inflammation and fibrosis and reduced IL‐1&bgr; and TGF‐&bgr;1 levels in bronchoalveolar lavage fluid(BALF). Pirfenidone substantially reduced NLRP3 and ASC expression and inhibited caspase‐1 activation and IL‐1&bgr; maturation in lung tissues. In vitro, the experiments revealed that PFD significantly suppressed LPS/ATP‐induced production of reactive oxygen species (ROS) and decreased caspase‐1 activation and the level of IL‐1&bgr; in J774A.1 cells. Taken together, the administration of PFD reduced LPS‐induced lung inflammation and fibrosis by blocking NLRP3 inflammasome activation and subsequent IL‐1&bgr; secretion. These findings indicated that PFD can down‐regulate NLRP3 inflammasome activation and that it may offer a promising therapeutic approach for ARDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bellani, G., Laffey, J. G., Pham, T., Fan, E., Brochard, L., Esteban, A., Gattinoni, L., van Haren, F., Larsson, A., McAuley, D. F., et al. (2016) · JAMA · doi:10.1001/jama.2016.0291 · Cited by 5,766
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 2×
“Pirfenidone, with an acceptable side-effect profile (King et al., 2014), is an oral antifibrosis drug that is successfully applied to the treatment of idiopathic”
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378 · cited 1×
“The NLRP3 inflammasome is capable of sensing a wide array of alarm signals, including ATP, uric acid crystals, LPS and various environmental irritants such as asbestos, silica and alum, leading to NLRP3 inflammasome activation (Jo et al., 2016).”
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · cited 1×
“Pirfenidone attenuates fibroblast proliferation and fibroblast differentiation into myofibroblasts and inhibits the expression of fibrogenic mediators, such as TGF-β, platelet-derived growth factor (PDGF)and IL-1β (Conte et al., 2014; Schaefer et al., 2011).”
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V. F. J., Ryffel, B., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1274oc · Cited by 410
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368
TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
Murray, L. A., Chen, Q., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Peng, X., Gulati, M., Homer, R. J., Russell, T., van Rooijen, N., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.013 · Cited by 362
Cited by
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
Dobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 268
Ying, H., Fang, M., Hang, Q. Q., Chen, Y., Qian, X., & Chen, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16821 · Cited by 131
Metadata
- Authors
- Li, Y., Li, H., Liu, S., Pan, P., Su, X., Tan, H., Wu, D., Zhang, L., Song, C., Dai, M., Li, Q., Mao, Z., Long, Y., Hu, Y., & Hu, C.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 99
- Pages
- 134-144
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W2803657718
- Cited by
- 158
- References
- 13
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.